A bacteria-based system expressing anti-TNF-α nanobody for enhanced cancer immunotherapy
Lina Liu, Xing Liu, Wenjie Xin, Lulu Zhou, Baolian Huang, Chao Han, Zhiting Cao, Zichun Hua
Abstract
As a successful drug for inflammatory diseases, the application of TNF-α inhibitor on cancer therapy is limited by repeated administration and off-target effects. 1 A body of evidence indicated that the anti-tumor efficacy of TNF-α inhibitor is unsatisfactory, though repeated administration was used to improve its efficacy in tumor-treating fields, it will also lead to severe side effects and high cost. 2 , 3 , 4 Hence, an efficient and highly targeted TNF-α antibody delivery system is worth developing.
Topics & Concepts
ImmunotherapyCancer immunotherapyBacteriaCancerTumor necrosis factor alphaCancer researchImmunologyMedicineBiologyComputational biologyMicrobiologyImmune systemGeneticsCancer Research and TreatmentsNanoplatforms for cancer theranosticsImmunotherapy and Immune Responses